comparemela.com

Latest Breaking News On - Sofinnova investments inc - Page 1 : comparemela.com

Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics

Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Mirum Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

03.08.2023 - Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for second quarter 2023 and provided a business update. “Our goal is to continue to bring life-changing medicines to patients with rare disease. Use of LIVMARLI in Alagille .

Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics

Mirum to acquire all of Travere’s rights and assets related to Cholbam® and Chenodal® Travere to receive up to $445 million with $210 million upfront and up to $235 million in potential sales-based milestones Mirum announces concurrent private placement of $210 million, funding upfront payment Expands Mirum’s leadership in rare liver disease with two commercial products and a near-term Phase 3 label expansion opportunity Advances Travere’s strategy to deliver new treatment standards from its pipeline of innovative medicines for rare diseases and strengthens financial foundation Mirum to host conference call today, July 17, 2023, at 8:30 a.m. ET/5:30 a.m. PT

Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics

Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

Zentalis Pharmaceuticals, Inc (NASDAQ:ZNTL) Insider Sells $2,401,600 00 in Stock

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating) insider Kevin D. Bunker sold 80,000 shares of the company’s stock in a transaction that occurred on Friday, May 26th. The shares were sold at an average price of $30.02, for a total value of $2,401,600.00. Following the completion of the sale, the insider now owns 15,000 shares […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.